Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of ABBV-438 in relapsed or refractory multiple myeloma
jRCT2031260209Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of ABBV-438 in multiple myeloma (MM), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability of ABBV-438. Started Jun 2026; status: recruiting.
02
Drugs
ABBV-438
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031260209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260209.